Lead Sponsor

Pfizer

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

No

•Men or women age \> 65 years.
•A primary diagnosis of Generalized Anxiety Disorder according to the Diagnostic and Statistical Manual-IV (DSM-IV).
•Subjects must have a HAM-A score of 16 or higher at both screening and baseline visits.

•Women who are pregnant or contemplating pregnancy (eg, via in vitro fertilization) during the study through 30 days after the last dose of study medication.
•Subjects with evidence of a current (within the past 6 months) clinically significant or unstable hematological, autoimmune, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, psychiatric, neurologic, immunological or retinal disorder; subjects with an active infection within the past 2 months.
•Subjects who have an ongoing, unresolved, clinically significant cardiovascular or cerebrovascular medical problem.
•Mini Mental Status Exam (MMSE) score \<24 or possibility of undiagnosed dementia, cognitive or amnestic disorder, including, but not limited to mild cognitive impairment.

Related studies

NCT06804525 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more

NCT07429578 · Generalized Anxiety Disorder (GAD), Chronic Insomnia

NCT06661460 · ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Specific Phobia, and more

NCT05467683 · Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, and more

NCT06846320 · Generalized Anxiety Disorder (GAD)

6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)